1921
Volume 85, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

The efficacy of praziquantel for the treatment of in humans is reported from a cross-sectional survey conducted in 33 villages in Sichuan Province. Infection prevalence was found to be 5.7% (185 infected of 3,269 tested) in a region where 44–73% prevalence was found 9 years before. Collected miracidia were subjected to an test of praziquantel susceptibility. An effective concentration of praziquantel associated with 50% of miracidia changing shape was found between 10 and 10 M and 10 and 10 M for 10 and 5 minutes of exposure, respectively. After treating infected persons two times with 40-mg/kg doses of praziquantel, only one remained infected. Findings are reported from a 60-household questionnaire on attitudes and behaviors that may be associated with development of drug resistance. The low number of treatment failures and good compliance with treatment despite side effects and repeated annual treatments suggest that, in the near term, praziquantel remains effective in treating human infection in China.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.2011.10-0542
2011-07-01
2019-11-23
Loading full text...

Full text loading...

/deliver/fulltext/14761645/85/1/074.html?itemId=/content/journals/10.4269/ajtmh.2011.10-0542&mimeType=html&fmt=ahah

References

  1. Cioli D, Pica-Mattoccia L, , 2003. Praziquantel. Parasitol Res 90 (Supp 1): S3S9. [Google Scholar]
  2. Cioli D, Pica-Mattoccia L, Secor W, Colley D, , 2005. Current and future antischistosomal drugs. , eds. Schistosomiasis. New York, NY: Springer, 191206.[Crossref] [Google Scholar]
  3. James C, Webbe G, Nelson GS, , 1977. Susceptibility to praziquantel of Schistosoma haematobium in baboon (Papio-Anubis) and of Schistosoma japonicum in vervet monkey (Cercopithecus aethiops). Z Parasitenkunde-Parasitology Res 52: 179194.[Crossref] [Google Scholar]
  4. Webbe G, James C, , 1977. Comparison of susceptibility to praziquantel of Schistosoma-haematobium, Schistosoma japonicum, S. mansoni, Schistosoma intercalatum and Schistosoma mattheei in hamsters. Z Parasitenkunde-Parasitology Res 52: 169177.[Crossref] [Google Scholar]
  5. Leopold G, Ungethum W, Groll E, Diekmann HW, Nowak H, Wegner DH, , 1978. Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes. An example of a complex study covering both tolerance and pharmacokinetics. Eur J Clin Pharmacol 14: 281291.[Crossref] [Google Scholar]
  6. Ishizaki T, Kamo E, Boehme K, , 1979. Double-blind studies of tolerance to praziquantel in Japanese patients with Schistosoma japonicum infections. Bull World Health Organ 57: 787791. [Google Scholar]
  7. Katz N, Rocha R, Chaves A, , 1979. Preliminary trials with praziquantel in human infections due to Schistosoma mansoni . Bull World Health Organ 57: 781785. [Google Scholar]
  8. Davis A, Biles JE, Ulrich AM, , 1979. Initial experiences with praziquantel in the treatment of human infections due to Schistosoma haematobium . Bull World Health Organ 57: 773779. [Google Scholar]
  9. Shou-Pai M, Bao-Ruo S, , 1982. Schistosomiasis control in the People's Republic of China. Am J Trop Med Hyg 31: 9299. [Google Scholar]
  10. Chen MG, , 2005. Use of praziquantel for clinical treatment and morbidity control of schistosomiasis japonica in China: a review of 30 years' experience. Acta Trop 96: 168176.[Crossref] [Google Scholar]
  11. Ross AG, Sleigh AC, Li Y, Davis GM, Williams GM, Jiang Z, Feng Z, McManus DP, , 2001. Schistosomiasis in the People's Republic of China: prospects and challenges for the 21st century. Clin Microbiol Rev 14: 270295.[Crossref] [Google Scholar]
  12. Utzinger J, Zhou XN, Chen MG, Bergquist R, , 2005. Conquering schistosomiasis in China: the long march. Acta Trop 96: 6996.[Crossref] [Google Scholar]
  13. Yuan H, Jiang Q, Zhao G, He N, , 2002. Achievements of schistosomiasis control in China. Mem Inst Oswaldo Cruz 97 (Suppl 1): 187189.[Crossref] [Google Scholar]
  14. Wegner DH, , 1984. The profile of the trematodicidal compound praziquantel. Arzneimittelforschung 34: 11321136. [Google Scholar]
  15. Xiao SH, Booth M, Tanner M, , 2000. The prophylactic effects of artemether against Schistosoma japonicum infections. Parasitol Today 16: 122126.[Crossref] [Google Scholar]
  16. Liang YS, Dai JR, Ning A, Yu DB, Xu XJ, Zhu YC, Coles GC, , 2001. Susceptibility of Schistosoma japonicum to praziquantel in China. Trop Med Int Health 6: 707714.[Crossref] [Google Scholar]
  17. Botros S, Sabra A, William S, , 2008. Miracidial assay as a simple, inexpensive biological test for sensitivity to praziquantel (pzq) using field and laboratory pzq-susceptible and insusceptible Schistosoma mansoni isolates. Aust J Basic Appl Sci 2: 677684. [Google Scholar]
  18. Spear RC, Seto E, Liang S, Birkner M, Hubbard A, Qiu D, Yang C, Zhong B, Xu F, Gu X, Davis GM, , 2004. Factors influencing the transmission of Schistosoma japonicum in the mountains of Sichuan Province of China. Am J Trop Med Hyg 70: 4856. [Google Scholar]
  19. Seto EY, Lee YJ, Liang S, Zhong B, , 2007. Individual and village-level study of water contact patterns and Schistosoma japonicum infection in mountainous rural China. Trop Med Int Health 12: 11991209.[Crossref] [Google Scholar]
  20. Katz N, Chaves A, Pellegrino J, , 1972. A simple device for quantitative stool thick-smear technique in schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo 14: 397400. [Google Scholar]
  21. Renganathan E, Cioli D, , 1998. An international initiative on praziquantel use. Parasitol Today 14: 390391.[Crossref] [Google Scholar]
  22. Remais J, Chen L, Seto E, , 2009. Leveraging rural energy investment for parasitic disease control: schistosome ova inactivation and energy co-benefits of anaerobic digesters in rural China. PLoS One 4: e4856.[Crossref] [Google Scholar]
  23. Liang S, Seto EY, Remais JV, Zhong B, Yang C, Hubbard A, Davis GM, Gu X, Qiu D, Spear RC, , 2007. Environmental effects on parasitic disease transmission exemplified by schistosomiasis in western China. Proc Natl Acad Sci USA 104: 71107115.[Crossref] [Google Scholar]
  24. Lamberton PH, Hogan SC, Kabatereine NB, Fenwick A, Webster JP, , 2010. In vitro praziquantel test capable of detecting reduced in vivo efficacy in Schistosoma mansoni human infections. Am J Trop Med Hyg 83: 13401347.[Crossref] [Google Scholar]
  25. Polderman AM, Gryseels B, Gerold JL, Mpamila K, Manshande JP, , 1984. Side effects of praziquantel in the treatment of Schistosoma mansoni in Maniema, Zaire. Trans R Soc Trop Med Hyg 78: 752754.[Crossref] [Google Scholar]
  26. Santos AT, Blas BL, Nosenas JS, Portillo GP, Ortega OM, Hayashi M, Boehme K, , 1979. Preliminary clinical trials with praziquantel in Schistosoma japonicum infections in the Philippines. Bull World Health Organ 57: 793799. [Google Scholar]
  27. Wu MH, Wei CC, Xu ZY, Yuan HC, Lian WN, Yang QJ, Chen M, Jiang QW, Wang CZ, Zhang SJ, , 1991. Comparison of the therapeutic efficacy and side effects of a single dose of levo-praziquantel with mixed isomer praziquantel in 278 cases of schistosomiasis japonica. Am J Trop Med Hyg 45: 345349. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2011.10-0542
Loading
/content/journals/10.4269/ajtmh.2011.10-0542
Loading

Data & Media loading...

  • Received : 27 Sep 2010
  • Accepted : 08 Apr 2011
  • Published online : 01 Jul 2011

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error